$900,000 over two years will go toward enhancing the peptide manufacturing and delivery technologies.
Unigene Laboratories received a $900,000 funding to advance it’s discovery program related to therapeutic peptide hormones. The phase II SBIR grant from the National Institute for Diabetes and Digestive Kidney Diseases will be provided over two years.
In 2003, Unigene received a phase I grant, which allowed the company to utilize the technology it developed in collaboration with the University of South Florida to establish a procedure for identifying such peptides in various plant or animal tissues.
“An increasing number of peptides are being shown to play essential roles in fundamental human metabolic processes, yet only a small number of these have already been commercialized,” states Ronald S. Levy, M.D., executive vp of Unigene. “This program can create additional opportunities for the utilization of Unigene’s peptide manufacturing and delivery technologies, while enabling us to obtain additional patent protection on the novel peptides themselves.”
